Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 14/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 5/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12503372 | 0.88 | MET (0.44) | WEE1METSRCFGFR1ABL1 | |
| SCHEMBL14077636 | 0.84 | L3MBTL1 (0.41) | WEE1METSRCCYP1A2 | |
| SCHEMBL4435587 | 0.84 | MET (0.41) | WEE1METPDGFRBPDGFRACYP2C9 | |
| SCHEMBL3557223 | 0.82 | MET (0.41) | METCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3564189 | 0.77 | MET (0.44) | WEE1METSRCPDGFRBPDGFRA | |
| SCHEMBL2282607 | 0.75 | MET (0.47) | WEE1METSRCFGFR1 | |
| SCHEMBL2288757 | 0.74 | MET (0.58) | WEE1METCYP1A2EGFRFGFR2 | |
| SCHEMBL12561198 | 0.74 | CYP1A2 (0.48) | WEE1METSRCCYP1A2CYP3A4 | |
| SCHEMBL2278282 | 0.73 | WEE1 (0.45) | WEE1METCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11481093 | 0.73 | ALDH1A1 (0.47) | WEE1METSRCCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687522-B2 | Substituted pyridines and pyrimidines and their use in treatment of cancer | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687522-B2 | Substituted pyridines and pyrimidines and their use in treatment of cancer | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687522-B2 | Substituted pyridines and pyrimidines and their use in treatment of cancer | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-2125781-A2 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | Amgen Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080214544-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214544-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214544-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008079291-A2 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079291-A2 | SUBSTITUTED HETEROCYCLES AND METHODS OF USE | AMGEN INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214544-A1 | Substituted heterocycles and methods of use | HGF, MET, HGFAC | WEE1 975/4885MET 2/4885SRC 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.